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Prevention offers the most cost-effective long-term
strategy for the control of cancer and at least one-third
of all malignancies are preventable. A number of strate-
gies have been developed over the last decades to pro-
vide opportunities for cancer prevention at different
levels: primary prevention by reducing levels of exposure
to high risk factors or causative agents, secondary pre-
vention through establishment of cancer screening pro-
grams and tertiary prevention with interventions aimed
at the modification of cancer outcomes, such as clinical
trials and tailored therapies. In this scenario, the identi-
fication of individuals at high risk of developing certain
cancers can provide an important opportunity for pre-
vention, at different levels. The example of breast cancer
will be used to further explore this concept.
Breast cancer is a significant health care problem
worldwide. Among women with this diagnosis, a subset
of patients with previously identifiable risk factors can be
easily recognized. Two main groups of high-risk women
can be described. The first is composed of women with a
significantly increased lifetime risk of developing the dis-
ease when compared to the general population, and this
is due to a combination of reproductive, behavioral and
low-penetrance, common genetic risk factors. Several
mathematical models have been developed to identify
this subset of women, and specific risk-reducing inter-
ventions have been proposed (i.e. annual magnetic reso-
nance imaging of the breast for women with estimated
lifetime risks of breast cancer over 20% and chemopre-
vention for women with and estimated breast cancer risk
greater than 1,66% in five years). A significant proportion
of women, at the populational level may benefit from
cancer risk assessment. In Southern Brazil, for instance, a
population-based study of 9,128 women from the public
primary health care system identified a lifetime breast
cancer risk estimate > 20% in 8% of women in that
cohort [1]. On the other hand, a study from the same
region, involving 3,665 cancer-unaffected women
between the ages of 40 and 69 years undergoing screen-
ing mammography, identified a significant 5-year breast
cancer risk in approximately 7% [2]. Breast cancer risk
estimation is important not only to direct the medical
management of the patients, but has also been described
as an important and independent predictor of adherence
to mammographic breast cancer screening. Although the
benefits of chemoprevention have been demonstrated in
several large prospective clinical trials, less than one in
every 10 women at high risk for breast cancer discussed
her risk with a physician or was considered for risk redu-
cing chemotherapy [3]. Thus, an effort should be under-
taken not only to increase the identification of high risk
patients, but also to further investigate risk reducing
interventions for this group.
The second group of women at high risk for breast
cancer are those who carry a germline mutation related
to hereditary predisposition to the disease. Hereditary
cancer syndromes underly 5-20% of all breast tumors and
carriers have a significantly increased risk of developing
multiple tumors at an early age [4]. The identification of
hereditary cancer patients and families is essential to
ensure accurate risk assessment, implementation of
appropriate risk-reducing interventions and effective
genetic counseling. Several hereditary breast cancer syn-
dromes have been identified to date and mutations in
many different genes have been described with these
forms of the disease including those in BRCA1, BRCA2,
TP53, PTEN, ATM, among others. The magnitude of risk
associated with mutation carriage is significant, i.e. car-
riers of mutations in the BRCA1 and BRCA2 genes have
an estimated lifetime risk of 70-85%, compared to the
lifetime risk of women in the general population which is
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close to 10%. In addition, women with these mutations
are at increased risk for contralateral breast tumors
(40-60%) compared to those without genetic forms of the
disease (5%). Taking the same example of hereditary
breast and ovarian cancer syndrome due to BRCA muta-
tions, several strategies for preventive interventions have
been developed over the last two decades, including risk
reducing surgeries, intensified and early-onset cancer
screening and development of targeted therapies for
tumors mainly caused by hereditary mutations. On the
other hand, several challenges are still present in the
diagnosis and management of hereditary breast cancer.
These include our still limited knowledge of the func-
tional impact of certain sequence alterations in known
cancer predisposition genes, the absence of specific can-
cer predisposing mutations in certain cases (even with an
obvious hereditary phenotype), the occurrence of signifi-
cant phenotypic overlap between the different syndromes
rendering molecular diagnosis a difficult task in certain
situations and the low sensitivity and specificity of cri-
teria currently used to define syndromes by cancer family
history. Finally, there is also limited understanding of the
impact of genetic modifiers and environment on the phe-
notype in hereditary cancer families, as well as limited
knowledge on population-specific or geographically loca-
lized mutations. As example we can cite a population-
specific situation related to a founder germline mutation
in the tumor suppressor gene TP53.
The exact contribution of TP53 germline mutations to
the overall burden of cancer is still only partially known
[5]. Most of the current evidence comes from studies on
few families that carry highly predisposing, hotspot TP53
mutations (TP53 mutation database). Studies in Brazil
have shown that a particular mutant, p.R337H, has incom-
plete penetrance and may be present in a significant num-
ber of subjects due to a founder effect (estimated
frequency at the populational level of 1:300 individuals in
certain regions), which may not easily recognized as risk
patients due to weak family history of the disease and/or
later onset of tumors [6,7]. This observation raises two
points: (a) the occurrence of cancer-predisposing TP53
germline mutations may be much more common than
recognized so far. This is likely the case in Southern and
Southeastern Brazil for p.R337H, but may also occur in
other Brazilian regions, or other parts of the world, due to
similar founder mutations of incomplete penetrance; and
(b) the cohort of p.R337H subjects and patients from Bra-
zil provides a basis for both mechanistic and clinical
studies.
In a recent study designed to assess the prevalence of p.
R337H in breast cancer-affected women the mutation was
present in breast cancer affected women with positive
familial histories but no phenotypic criteria for LFS/LFL
syndromes, and in a significant proportion (average
among different Brazilian regions ˢ8%) of women with
breast cancer and unselected for familial cancer history
[8]. Mutation prevalence was significantly higher in
women with breast cancer at ≤ 45 years (12·1%) than at
≥ 55 years (5·1%, p<0·001) and analysis of breast tumour
tissues from mutation carriers revealed that loss of hetero-
zygosity (LOH) was not a frequent event, different from
the expected for disease-causing mutations in tumor sup-
pressor genes. The results showed that, taking into
account an estimated population prevalence of 0·3% for
the Brazilian founder p.R337H allele, mutation carriers are
over-represented by about 40 fold among BC patients
(≤ 45 years) and by about 17 fold among late onset BC
patients (≥ 55 years), suggesting that inheritance of this
mutation significantly contributes to the high incidence of
breast cancer observed in many parts of Brazil. This is
likely the most common germline TP53 mutation identi-
fied so far, and identification of carriers will have signifi-
cant impact on design of public health interventions
related to cancer control in Brazil.
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